Catabasis Pharma (CATB) Forecast, Price Target & Analyst Ratings

NASDAQ:CATB

Current stock price

8.54
-0.64 (-6.97%)
At close:
8.63
+0.09 (+1.05%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Catabasis Pharma (CATB).

Forecast Snapshot

Consensus Price Target

Price Target
$24.23
+ 183.67% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2021
EPS Estimate
-$0.83
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
100.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$24.23
Upside
+ 183.67%
From current price of $8.54 to mean target of $24.23, Based on 4 analyst forecasts
Low
$13.13
Median
$23.46
High
$37.80

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

4 Wall Street analysts provided a forecast for the next 12 months for CATB. The average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CATB Current Analyst RatingCATB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CATB Historical Analyst RatingsCATB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 0 0 0 0 0

Analyst Ratings Consensus

ChartMill Buy Consensus
100.00%
CATB was analyzed by 4 analysts. The buy percentage consensus is at 100. So analysts seem to be very confident about CATB.
In the last month the buy percentage rose by 13 points. So the trust of analysts is improving.
Only 4 analysts analyzed CATB. So this is just the average opinion of a couple of analysts.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2021-09-02WedbushInitiate Outperform
2021-08-25HC Wainwright & Co.Upgrade Neutral -> Buy
2021-05-12Ladenburg ThalmannInitiate Buy
2021-03-11OppenheimerUpgrade Perform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2021
EPS Estimate
-$0.83
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-48.76%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2021 - 2025

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
CATB revenue by date.CATB revenue by date.
N/AN/AN/AN/A
-100.00%		N/AN/AN/AN/AN/AN/AN/A
EBITDA
YoY % growth
CATB ebitda by date.CATB ebitda by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CATB ebit by date.CATB ebit by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Operating Margin
CATB operating margin by date.CATB operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CATB eps by date.CATB eps by date.
N/A-22.30
90.34%		-12.80
42.60%		-6.90
46.09%		-2.35
65.94%		-4.23
-80.00%		N/A
-561.19%		N/A
88.56%		N/A
3.62%		N/A
-43.22%		N/A

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 21 Q4 / 21 Q1 / 22 Q2 / 22 Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.83
-48.76%		-0.96
63.81%		-0.67
53.25%		-0.67
46.57%		-0.80
4.49%		-0.98
-2.49%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/AN/A

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CATB Yearly Revenue VS EstimatesCATB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 100K 200K 300K
CATB Yearly EPS VS EstimatesCATB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
8.32%
EPS Next 5 Year
-0.87%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

Catabasis Pharma / CATB Forecast FAQ

Can you provide the average price target for Catabasis Pharma stock?

4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.

What are the consensus estimates for CATB stock next earnings?

The consensus EPS estimate for the next earnings of Catabasis Pharma (CATB) is -0.83 null and the consensus revenue estimate is 0 null.